Repeated Dose Phase I Study of FYU-981
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: FYU-981, (Oral daily dosing for 7 days)Drug: Placebo, (Oral daily dosing for 7 days)
- Registration Number
- NCT02348333
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Brief Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of 7-day-repeated doses of FYU-981 administered orally to healthy male adults once daily. Participants are randomized to placebo (n=3) or FYU-981 (n=6) in each step. After follow-up examination in the step of lower dose, the next dose is administered.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 18
Inclusion Criteria
- Japanese healthy adult subjects
- Body mass index: >=18.5 and <25.0
Exclusion Criteria
- Subjects with any disease or any history of diseases that might be unsuitable for participation in the clinical study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description FYU-981 FYU-981, (Oral daily dosing for 7 days) - Placebo Placebo, (Oral daily dosing for 7 days) -
- Primary Outcome Measures
Name Time Method Pharmacokinetics (Cmax: Maximum plasma concentration) 1-, 4-, and 7-day Pharmacokinetics (Cmin: Minimum plasma concentration) 1-, 2-, 3-, 4-, 5-, 6- and 7-day Pharmacokinetics (Tmax: Time to reach the peak plasma concentration) 1-, 4-, and 7-day Pharmacokinetics (T1/2: Elimination half-life of plasma concentration) 1-, 4-, and 7-day Pharmacokinetics (AUC: Area under the plasma concentration-time curve) 1-, 4-, and 7-day Pharmacokinetics (Rauc: Accumulation ratio of AUC0-24) 4-, and 7-day Pharmacokinetics (kel: Elimination rate constant) 1-, 4-, and 7-day Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed) 1-, 4-, and 7-day Pharmacokinetics (Ae: Amount of drug excreted in urine) 9 days Pharmacokinetics (fe: Fraction of dose excreted in urine) 9 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular targets and mechanisms of action of FYU-981 in healthy subjects?
How does the pharmacokinetic profile of FYU-981 compare to other Phase I oral drug candidates in healthy adults?
Are there specific biomarkers associated with pharmacodynamic responses to FYU-981 in early clinical trials?
What adverse event management strategies were implemented in the 7-day repeated dosing of FYU-981 in healthy males?
What is the therapeutic potential of FYU-981 in relation to other investigational drugs from Fuji Yakuhin Co., Ltd.?
Trial Locations
- Locations (1)
Japan
🇯🇵Tokyo, Japan
Japan🇯🇵Tokyo, Japan